Loss of Dopamine Transporter Binding in Parkinson’s Disease Follows a Single Exponential Rather Than Linear Decline

Johannes Schwarz, MD; Alexander Storch, MD; Walter Koch, MD; Oliver Pogarell, MD; Perry E. Radau, PhD; and Klaus Tatsch, MD

1Department of Neurology, University of Leipzig, Leipzig, Germany; 2Department of Neurology, University of Ulm, Ulm, Germany; 3Department of Nuclear Medicine, Ludwig-Maximilians-University, Munich, Germany; 4Department of Psychiatry, Ludwig-Maximilians-University, Munich, Germany; and 5Imaging Research, Sunnybrook and Women’s College Health Sciences Centre, Toronto, Ontario, Canada

Imaging of L-dopa uptake or dopamine transporter binding can monitor the progression of Parkinson’s disease. Most follow-up studies have provided data best fitted by a linear decline of their outcome measure. However, in these studies, patients were repeatedly scanned during their first years after a diagnosis had been established. Methods: We followed 6 patients with early Parkinson’s disease for 7.5 y using 123I-labeled N-(3-iiodopro-pene-2-yl)-2β-carboxmethoxy-3β-(4-chlorophenyl) tropane and SPECT. Results: Loss of dopamine transporter binding was best fitted using a single exponential approximation. A 63% loss (τ [time constant tau]) was calculated as 5.18 ± 7.62 y in the putamen and 10.62 ± 31.4 y in the caudate nucleus when a 3-parameter fit was used. Conclusion: These data approximate, for what is to our knowledge the first time, the decline of dopamine transporter binding as expected in biologic systems and may allow for models that correct for exponential decline to be developed and for disease-modifying effects in patients with advanced disease to be determined.

Key Words: Parkinson’s disease; dopamine transporter; SPECT; rate of decline


Parkinson’s disease (PD) is characterized by a progressive loss of dopaminergic neurons in the substantia nigra and their striatal terminals. Striatal dopaminergic innervation may be quantitatively assessed using radiolabeled L-dopa, ligands of the dopamine transporter (DAT), or the vesicular monoamine transporter 2. Specific uptake of these radiopharmaceuticals is measured using PET or SPECT (1,2). Intraindividual studies have served to calculate the rate of functional decline of dopaminergic neurons in PD and to estimate the duration of the preclinical period. Most follow-up studies have shown an annual decline ranging from 5% to 10% (3–7) and seeming to be stable during the follow-up period. However, in these studies patients were initially in an early stage of disease and were followed for only up to 5 y. Data assessed in intraindividual studies have already been used to design large-scale clinical trials investigating the effect of various drugs on the progression of PD (8,9).

Previously, we reported follow-up data on 8 patients with early PD who underwent DAT SPECT scans 1 and 2 y after an initial scan (10). In this earlier study, annual rates of decline ranged from 5% to 7% and were stable during the 2-y observation period. Our present report extends this observation. Six of the 8 patients were recruited for a 7.5-y follow-up scan.

MATERIALS AND METHODS

The patients were described in detail in our previous report (10). All patients fulfilled the diagnostic criteria of the Parkinson’s Disease Society brain bank (11). All patients were treated with L-dopa and a dopamine agonist. Three patients received additional amantadine. Treatment was basically unchanged except for dosage adjustments and introduction of entacapone in 2 patients. All studies were performed without discontinuation of therapy. The mean duration of disease before the first scan was 3.2 y, and the range was 1–6 y.

Baseline and follow-up SPECT studies were performed according to a standardized protocol. We used the 123I-labeled cocaine analog N-(3-iiodopropene-2-yl)-2β-carboxmethoxy-3β-(4-chlorophenyl) tropane (IPT), which has proven to be a reliable diagnostic tool for classifying the extent and degree of dopaminergic nerve cell loss in various clinical studies (10,12,13) and which may be reproducibly analyzed with low intra- and interobserver variability in PD patients (14). Ninety minutes after intravenous injection of 150 MBq of 123I-IPT, scans were acquired on a triple-head γ-camera (Prism 3000; Picker) using high-resolution fanbeam collimators, a rotational radius of 12.7–13 cm, 120 projections, 45 s per view, and a 128 × 128 matrix. Data were reconstructed by filtered backprojection, postfiltered with a low-pass filter (cutoff, 0.27; 5th order), corrected for attenuation (first-order method of Chang), and
All patients showed markedly reduced striatal DAT binding in every examination. This reduction was already statistically significant, compared with the values in healthy volunteers during the first scan ($P < 0.001$). Specific IPT binding steadily declined during the follow-up period. Table 1 summarizes specific uptake ratios at baseline and at 1, 2, and 7.5 y of follow-up, respectively.

![Graph showing DAT binding ratios over time](image)

**FIGURE 1.** In patients with PD, data on 7.5-y follow-up of striatal DAT binding. Data are best fitted by a single exponential decay (solid line). Extrapolation of calculated single exponential decline hits control values 4–5 y before the first scan (dashed line). The 3 initial patient scans are well fitted by a linear decline (dotted line).

For calculation of a putative preclinical period, we entered the mean uptake ratio of our control group into the calculated equation. The theoretic period between the first

### RESULTS

Specific $^{123}$I-IPT uptake ratios in healthy volunteers ($n = 9$) were calculated as $2.88 \pm 0.15$ (mean $\pm$ SD), $3.03 \pm 0.14$, and $2.79 \pm 0.13$ in the striatum ($[S - FC]/FC$), caudate ($[C - FC]/FC$), and putamen ($[P - FC]/FC$), respectively.

All patients showed markedly reduced striatal DAT binding in every examination. This reduction was already statistically significant, compared with the values in healthy volunteers during the first scan ($P < 0.001$). Specific IPT binding steadily declined during the follow-up period. Table 1 summarizes specific uptake ratios at baseline and at 1, 2, and 7.5 y of follow-up, respectively.

![Graph showing data analysis](image)

**TABLE 1**

Uptake Ratios, Time Constants, and Correlation Coefficients Using a Single Exponential Decay Fit

<table>
<thead>
<tr>
<th>Region</th>
<th>0 y</th>
<th>1 y</th>
<th>2 y</th>
<th>7.5 y</th>
<th>1/τ (y)</th>
<th>$R^2$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Striatum</td>
<td>1.65 ± 0.14</td>
<td>1.50 ± 0.19</td>
<td>1.31 ± 0.14</td>
<td>0.78 ± 0.10</td>
<td>6.65 ± 10.25</td>
<td>0.9992</td>
</tr>
<tr>
<td>Putamen</td>
<td>1.22 ± 0.16</td>
<td>1.10 ± 0.17</td>
<td>0.94 ± 0.12</td>
<td>0.56 ± 0.08</td>
<td>5.18 ± 7.62</td>
<td>0.9986</td>
</tr>
<tr>
<td>Caudate</td>
<td>2.03 ± 0.18</td>
<td>1.87 ± 0.26</td>
<td>1.66 ± 0.21</td>
<td>0.96 ± 0.14</td>
<td>10.62 ± 31.4</td>
<td>0.9995</td>
</tr>
</tbody>
</table>
scan in our patients and control values was calculated as 4.79 y for the striatum, 5.25 y for the putamen, and 4.26 y for the caudate nucleus. Because the mean duration between onset of clinical symptoms and the first IPT SPECT investigation was 3.2 y, the preclinical period calculated according to these DAT binding data may be considerably shorter than 5 y.

**DISCUSSION**

In this study, we were able to demonstrate that the rate of decline of DAT binding very well fits a single exponential decline during early to moderate PD. Another recent trial again argued for stable relative loss of DAT binding over a 5-y period (18). Although these data may disagree with ours, the observation period may have been too variable and too short to stably show the exponential decay. Although our data nicely match the anticipated time course of loss of function in biologic systems, we need to raise caution because of the limited number of data points and the small number of patients.

Extrapolating the single exponential decline to the preclinical period leads to control values 2–3 y before the onset of symptoms. We cannot exclude that the loss of function of dopaminergic neurons may not parallel the loss of DAT binding. Especially during the preclinical phase of PD, the loss of dopaminergic function could be substantially slower than in the clinical phase, thus necessitating the use of more than one exponent to approximate the decline of dopaminergic function, resulting in a longer estimation of the preclinical period. It is also likely that the rate of decline during the very early phase of the disease is considerably slower, thus arguing for a polynomial approximation and a much longer preclinical period. Because of the lack of respective data, these considerations remain speculative.

Imaging of DATs as a surrogate marker for disease progression has been introduced into clinical trials of PD patients (9). This trial demonstrated that DAT binding showed a milder decline in patients receiving a dopamine agonist than in those receiving L-dopa. One major argument against the disease-modifying effect of pramipexole proven by this study was that the percentage changes, compared with baseline, did not continue to diverge between the 2 treatment groups (19,20). However, if the rate of decline had also followed a single exponential pattern, this would not have been expected. In fact, when the data presented in this report were reconstructed (9), at least the binding ratios detected in the L-dopa group nicely matched a single exponential decline, in agreement with our present data. Also, the rate of decline (τ) seemed to be different between the 2 treatment groups, arguing for a disease-modifying effect of pramipexole, compared with L-dopa.

There has been intense discussion on whether imaging of DAT binding indeed reflects progression of PD and whether these data can be used to prove a protective effect (19,20). However, there also is sufficient evidence that functional imaging of dopaminergic nerve terminals provides a valuable adjunct to clinical rating scales when potential neuroprotective effects are assessed (21). We anticipate that significantly different time constants should distinguish between disease-modifying and drug effects. However, longer observation periods, larger patient groups, and multiple data points may be necessary to approximate meaningful time constants.

**CONCLUSION**

Here, we have provided evidence that the loss of DAT binding during early to moderate PD best fits a single exponential decline. Time constants may provide an accurate quantification. Using time constants as outcome measures in “neuroprotection” trials in patients with PD may allow the inclusion of patients with more advanced disease. Current neuroprotection trials always aim at patients with very early disease, or “de novo patients,” who are difficult to recruit. Thus, analyzing the actual rate of decline using assessments of time constants and multiple follow-up scans may improve not only the relevance but also the feasibility of such trials.

**ACKNOWLEDGMENT**

We thank Dr. Georg Becker for critical review of the manuscript and advice on data modeling.

**REFERENCES**

12. Tatsch K, Schwartz J, Mozley PD, et al. Relationship between clinical features of Parkinson’s disease and presynaptic dopamine transporter binding assessed with


